National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 4) (PB 34 of 2020) (Cth)
PB 34 of 2020
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 4)
National Health Act 1953
___________________________________________________________________________
I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 29th April 2020
THEA DANIEL
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
___________________________________________________________________________
Name of Instrument
(1)This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 4).
(2)This Instrument may also be cited as PB 34 of 2020.
Commencement
This Instrument commences on 1 May 2020.
Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).
Schedule 1 Amendments
Schedule 1, after entry for Buprenorphine in the form Injection (modified release) 96 mg in 0.27 mL pre-filled syringe
insert:
| Injection (modified release) 100 mg in 0.5 mL pre-filled syringe | 20 | 1 | 0 |
Schedule 1, after entry for Buprenorphine in the form Injection (modified release) 128 mg in 0.36 mL pre-filled syringe
insert:
| Injection (modified release) 300 mg in 1.5 mL pre-filled syringe | 20 | 1 | 0 |
Schedule 1, entry for Sapropterin
substitute:
| Sapropterin | Powder for oral solution 500 mg (as dihydrochloride) | 20 | 30 | 5 |
| Tablet (soluble) containing sapropterin dihydrochloride 100 mg | 20 | 180 | 5 |
Schedule 1, after entry for Umeclidinium with vilanterol
insert:
| Upadacitinib | Tablet 15 mg | 20 | 28 | 3 |
| 20 | 28 | 5 |
0
0
0